Replies to post #9993 on Arch Therapeutics Inc (ARTH)

[Polyphemus]

M&A transactions in this space are based on a synthesis of revenue/EBITDA history and pro forma (projections) DCF's, not share price or trading history. A 30 cents/share with a float of 171 million shares would imply a market cap/price of $51M. Based upon a history of no revenues after 18 months of FDA clearance and no real pipeline, what would you pay for ARTH if it were your company's money? One can always hope for stock trader enthusiasm to produce a spike in share price for an investor exit. Perhaps some presentation at a conference will a bout of euphoria.